$KURA News
Last published 1d ago
- 1d agoKURAKura Oncology, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1d agoKURAKura Oncology Reports Third Quarter 2026 Financial Results and Corporate UpdateGlobeNewswire– KOMZIFTI ® (ziftomenib) net product revenue grew 53% sequentially to $13.9 million; new patient starts increased 30% and total prescriptions grew 65% –
- 5d agoKURAKura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN DIEGO, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company focused on precision...
- 5d agoKURAKura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN DIEGO, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the "Company") (NASDAQ:KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced that on
- 1w agoKURAKura Oncology and Kyowa Kirin to Present First Ziftomenib-FLT3 Inhibitor Clinical Data at ASH 2026GlobeNewswire– Two oral presentations to feature first ziftomenib combination data with quizartinib in newly diagnosed and gilteritinib in relapsed/refractory NPM1/FLT3 co-mutated AML – – Longer-term Phase 1b data for ziftomenib
- 1w agoKURAKura Oncology to Report Third Quarter Financial Results on November 10GlobeNewswireSAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced it will report its third quarter
- 4w agoKURAKURA ONCOLOGY VIRTUAL INVESTOR EVENT - KURA ONCOLOGY INCEarnings Call TranscriptsGood day, everyone. My name is Ryan, and I will be your conference operator today. At this time, I would like to welcome you to the Curio Oncology and Caspian Therapeutics Investors Call. All lines have been placed on mu
- 4w agoKURAKURA ONCOLOGY VIRTUAL INVESTOR EVENT - KURA ONCOLOGY INCEarnings Call TranscriptsGood day, everyone. My name is Ryan, and I will be your conference operator today. At this time, I would like to welcome you to the Curio Oncology and Caspian Therapeutics Investors Call. All lines have been placed on mu
- 4w agoKURAKura Oncology Virtual Investor Event - KURA ONCOLOGY INCEarnings Call TranscriptsGood day, everyone. My name is Ryan, and I will be your conference operator today. At this time, I would like to welcome you to the Curio Oncology and Caspian Therapeutics Investors Call. All lines have been placed on mu
- 4w agoKURACaspian Therapeutics and Kura Oncology Outline KO-7246 Development Strategy in DiabetesGlobeNewswire– EASD findings support clinical evaluation of a next-generation oral menin inhibitor designed to restore insulin-producing capacity – – IND-enabling development underway to support Phase 1 clinical proof-of-concept
- 1mo agoKURACaspian Therapeutics and Kura Oncology to Host Investor Webcast Highlighting Caspian’s Launch and KO-7246 Preclinical Data in DiabetesGlobeNewswireSAN DIEGO, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Caspian Therapeutics, Inc. ("Caspian") and Kura Oncology, Inc. (NASDAQ:KURA, "Kura")) today announced they will host an investor webcast on Tuesday, October
- 1mo agoKURAKura Oncology - 1773766 - KURA ONCOLOGY INCEarnings Call TranscriptsAll right. Thank you, everyone, for joining us. My name is Frank Tang, and I'm with the Investment Banking Division at Morgan Stanley. Thank you all for joining us today for the Fireside Chat with Cura Oncology. I am joi
- 1mo agoKURAMorgan Stanley 24th Annual Global Healthcare Conference - KURA ONCOLOGY INCEarnings Call TranscriptsAll right. Thank you, everyone, for joining us. My name is Frank Tang, and I'm with the Investment Banking Division at Morgan Stanley. Thank you all for joining us today for the Fireside Chat with Cura Oncology. I am joi
- 2mo agoKURAKura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for DiabetesGlobeNewswire– $50 million financing led by BVF Partners with participation from the T1D Fund, Invus, Montanova, Eli Lilly and Company, Kura Oncology, members of the Kura leadership team, and multiple, successful biotech
- 2mo agoKURAKura Oncology Appoints Jennifer Fulk as Chief Financial OfficerGlobeNewswire– Seasoned public company CFO with deep biopharmaceutical finance experience across commercial operations, R&D portfolio management, investor relations, and capital allocation – SAN DIEGO, Sept. 08, 2026 (GLOBE
- 2mo agoKURAKura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN DIEGO, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the "Company") (NASDAQ:KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced that on
- 2mo agoKURAKura Oncology to Participate in Three Investor Conferences in SeptemberGlobeNewswireSAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced that management will present at
- 3mo agoKURAKura Oncology Q2 2026 Earnings Call - KURA ONCOLOGY INCEarnings Call TranscriptsThank you. Thank you. Thank you. Thank you. Thank you for watching. Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. © transcript Emily Beynon Thank you. Thank you. Thank you. Thank you. Thank you. Thank
- 3mo agoKURAKura Oncology Reports Second Quarter 2026 Financial ResultsGlobeNewswire– KOMZIFTI® (ziftomenib) generated $9.1 million in net product revenue, up 57% over 1Q, and approximately 115 new patient starts, up 35% over 1Q – – KOMZIFTI® achieved majority share of new patient starts in R/R NPM1-m
- 3mo agoKURAKura Oncology Announces Publication in Blood Highlighting Ziftomenib’s Differentiated Binding Profile and Preclinical ActivityGlobeNewswire– Publication details the discovery and preclinical characterization of ziftomenib, including its potency, selectivity, and mechanism of action – – Findings demonstrate differentiated menin binding and activity against
- 3mo agoKURAKura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN DIEGO, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the "Company") (NASDAQ:KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of
- 3mo agoKURAKura Oncology to Report Second Quarter Financial ResultsGlobeNewswireSAN DIEGO, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced it
- 3mo agoKURAKura Oncology KCRS Virtual Investor Event - KURA ONCOLOGY INCEarnings Call TranscriptsGood day, everyone. my name is Stefan and I will be your conference operator today. At this time I'd like to welcome you to the... Coming in the relatively near term from our partners at Keokuren. if we could go to the n
- 3mo agoKURAKura Oncology Reports Durable Clinical Activity of Darlifarnib Plus Cabozantinib in Cabozantinib-Naïve Clear Cell Renal Cell Carcinoma Patients at KCRS 2026GlobeNewswire– Response rates up to 50% across evaluated dose levels and median PFS of 13 months observed in pre-treated, cabozantinib-naïve, locally advanced or metastatic ccRCC patients – – Activity compares favorably with
- 4mo agoKURAKura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026GlobeNewswire– Oral presentation will feature updated data from the FIT-001 Phase 1a study of darlifarnib plus cabozantinib in cabozantinib-naïve, advanced ccRCC patients – – Updated data expected to support darlifarnib’s potential
- 4mo agoKURAKura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN DIEGO, July 03, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the "Company") (NASDAQ:KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of
- 5mo agoKURAKura Oncology EHA Virtual Investor Event - KURA ONCOLOGY INCEarnings Call TranscriptsGood day, everyone. My name is Stefan, and I'll be your conference operator today. At this time, I'd like to welcome you to Cura Oncology's Investor Call to discuss the long-term results of Zystemenib and 7 plus 3 in new
- 5mo agoKURAKura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AMLGlobeNewswire– 12-month OS rate 94% among NPM1-m AML patients and 71% among KMT2A-r AML patients in single-arm KOMET-007 trial – – 96% CRc in newly diagnosed NPM1-m AML; 90% CRc in newly diagnosed KMT2A-r AML – – High rates of MRD
- 5mo agoKURAKura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN DIEGO, June 05, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the "Company") (NASDAQ:KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today
- 5mo agoKURAKura Oncology ASCO Virtual Investor Event - KURA ONCOLOGY INCEarnings Call TranscriptsThank you. © transcript Emily Beynon Thank you. Thank you. © transcript Emily Beynon Thank you. © transcript Emily Beynon Thank you. © transcript Emily Beynon Thank you. Thank you. Thank you. Thank you. Thank you for wat
- 5mo agoKURAKura Oncology Highlights Darlifarnib's Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development StrategyGlobeNewswire– Preliminary Phase 1a data from darlifarnib + adagrasib demonstrate confirmed, objective response rates of 67% in pancreatic cancer, 50% in non-small cell lung cancer, and 29% in KRAS inhibitor-naïve colorectal cancer
- 5mo agoKURAKura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AMLGlobeNewswire– 87% ORR and 70% CRc in venetoclax-naïve and 48% ORR and 24% CRc in venetoclax-experienced patients at the recommended 600 mg once-daily dose – – Central MRD negativity in 75% of CRc responders with no prior venetoclax
- 5mo agoKURAKura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid TumorsGlobeNewswire– Tumor shrinkage observed in 77% of response-evaluable patients, including in heavily pretreated and KRASi-experienced patients – – ORRs were 67% in PDAC, 50% in NSCLC, and 29% in KRASi-naïve CRC patients – – Results
- 5mo agoKURAKura Oncology to Present at TD Cowen 7th Annual Oncology Innovation SummitGlobeNewswireSAN DIEGO, May 19, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA) today announced its participation in the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA. Kura management is
- 6mo agoKURAKura Oncology Q1 2026 Financial Results - KURA ONCOLOGY INCEarnings Call TranscriptsGood day, everyone. My name is Layla, and I will be your conference operator today. At this time, I would like to welcome you to the Cura Oncology First Quarter 2026 Financial Results Earnings Call. All lines have been p
- 6mo agoKURAKura Oncology Reports First Quarter 2026 Financial ResultsGlobeNewswire– $5.8 million in KOMZIFTI™ (ziftomenib) net product revenue in first full quarter of commercialization – – Robust new patient starts and early launch dynamics, including repeat use, switching and combination
- 6mo agoKURAKura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 CongressGlobeNewswire– Oral presentation to feature 99-patient dataset with extended follow-up in newly diagnosed NPM1-m or KMT2A-r AML – – High CRc rates (90–96%) with deep MRD negativity (> 80%) across both subtypes – – Durable
- 6mo agoKURAKura Oncology to Participate in Bank of America Securities Healthcare ConferenceGlobeNewswireSAN DIEGO, May 06, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its
- 6mo agoKURAKura Oncology to Report First Quarter 2026 Financial ResultsGlobeNewswireSAN DIEGO, May 05, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced it will
- 6mo agoKURAKura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the "Company") (NASDAQ:KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today
- 6mo agoKURAKyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AMLGlobeNewswireTOKYO and SAN DIEGO, April 24, 2026 (GLOBE NEWSWIRE) -- Kyowa Kirin Co., Ltd. (TSE: 4151, "Kyowa Kirin") and Kura Oncology, Inc. (NASDAQ:KURA, "Kura")) today announced the first patient has been dosed in a Japanese
- 6mo agoKURAKURA ONCOLOGY IKCS VIRTUAL INVESTOR EVENT - KURA ONCOLOGY INCEarnings Call TranscriptsGood day, everyone. My name is Jenny and I'll be your conference operator today. At this time, I would like to welcome you to Cura Oncology's 2026 IKCS Investor Event. All lines have been placed on mute to prevent any ba
- 6mo agoKURAKura Oncology Reports Darlifarnib Plus Cabozantinib Demonstrates Robust Activity in Patients With Clear Cell Renal Cell Carcinoma Previously Treated With CabozantinibGlobeNewswireData from subset analysis of cabozantinib-pretreated patients support potential to overcome resistance and resensitize tumors to VEGF TKI therapy 44% ORR and 94% DCR in ccRCC patients previously treated with
- 7mo agoKURAKura Oncology to Present Darlifarnib Plus Cabozantinib Data in Patients with Clear Cell Renal Cell Carcinoma Previously Treated with Cabozantinib at IKCS Europe 2026GlobeNewswireData build on findings presented at ESMO 2025 and support potential of darlifarnib to overcome resistance and resensitize tumors to VEGFR TKI therapy Virtual investor call on April 17, 2026, at 7:30 a.m. PT / 10:30 a.m.
- 7mo agoKURAKura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN DIEGO, April 03, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the "Company") (NASDAQ:KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today
- 8mo agoKURAKura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN DIEGO, March 06, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the "Company") (NASDAQ:KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today
- 8mo agoKURAKura Oncology Reports Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewswire– KOMZIFTI™ (ziftomenib) launch generating early revenue momentum and rapid payer coverage decisions – – Market feedback emphasizes differentiated safety, combinability and convenience of ziftomenib, supporting
- 8mo agoKURAKura Oncology to Report Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewswireSAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced it will
- 8mo agoKURAKura Oncology to Participate in Three Upcoming Investor ConferencesGlobeNewswireSAN DIEGO, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its
- 9mo agoKURAKura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireSAN DIEGO, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the "Company") (NASDAQ:KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today